Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Acid phosphatase: defining a role in androgen-independent prostate cancer.

Steineck G, Kelly WK, Mazumdar M, Vlamis V, Schwartz M, Scher HI.

Urology. 1996 May;47(5):719-26.

PMID:
8650872
2.
3.

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB.

J Natl Cancer Inst. 1999 Feb 3;91(3):244-51.

PMID:
10037102
4.

Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.

Thatai LC, Banerjee M, Lai Z, Vaishampayan U.

Urology. 2004 Oct;64(4):738-43. Review.

PMID:
15491712
5.

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.

Smith JA Jr, Lange PH, Janknegt RA, Abbou CC, deGery A.

J Urol. 1997 Apr;157(4):1329-34.

PMID:
9120932
7.

Serum interleukin 6 as a prognostic factor in patients with prostate cancer.

Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M.

Clin Cancer Res. 2000 Jul;6(7):2702-6.

8.

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.

Matzkin H, Eber P, Todd B, van der Zwaag R, Soloway MS.

Cancer. 1992 Nov 1;70(9):2302-9.

9.

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.

J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.

PMID:
13130113
10.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
11.

Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.

Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ.

Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):631-4.

14.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
15.

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L.

Endocr Relat Cancer. 2005 Mar;12(1):109-17.

16.

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.

J Natl Cancer Inst. 2006 Apr 19;98(8):516-21.

PMID:
16622120
18.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM; Radiation Therapy Oncology Group Protocol 92-02.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. Epub 2006 Sep 18.

PMID:
16979837
19.

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.

Oefelein MG, Ricchiuti VS, Conrad PW, Goldman H, Bodner D, Resnick MI, Seftel A.

Urology. 2002 Jul;60(1):120-4.

PMID:
12100936

Supplemental Content

Support Center